Itaconic Acid: The Surprising Role of an Industrial Compound as a Mammalian Antimicrobial Metabolite by Cordes, Thekla et al.
NU35CH12-Hiller ARI 4 May 2015 15:10
R
E V
I E W
S
I
N
A D V A
N
C
E
Itaconic Acid: The Surprising
Role of an Industrial
Compound as a Mammalian
Antimicrobial Metabolite
Thekla Cordes,1,2,∗ Alessandro Michelucci,1,∗
and Karsten Hiller1
1Luxembourg Centre for Systems Biomedicine, University of Luxembourg, L-4362 Esch-Belval,
Luxembourg; email: thekla.cordes@uni.lu, alessandro.michelucci@uni.lu, karsten.hiller@uni.lu
2Current address: Department of Bioengineering, University of California, San Diego, La Jolla,
California 92093-0412; email: tcordes@eng.ucsd.edu
Annu. Rev. Nutr. 2015. 35:12.1–12.23
The Annual Review of Nutrition is online at
nutr.annualreviews.org
This article’s doi:
10.1146/annurev-nutr-071714-034243
Copyright c⃝ 2015 by Annual Reviews.
All rights reserved
∗Equal contributors
Keywords
metabolism, immune-responsive gene 1 protein (IRG1), macrophage,
cis-aconitic acid decarboxylase, metabolic immunity, inflammation
Abstract
Itaconic acid is well known as a precursor for polymer synthesis and has been
involved in industrial processes for decades. In a recent surprising discovery,
itaconic acid was found to play a role as an immune-supportive metabo-
lite in mammalian immune cells, where it is synthesized as an antimicrobial
compound from the citric acid cycle intermediate cis-aconitic acid. Although
the immune-responsive gene 1 protein (IRG1) has been associated to im-
mune response without a mechanistic function, the critical link to itaconic
acid production through an enzymatic function of this protein was only re-
cently revealed. In this review, we highlight the history of itaconic acid as
an industrial and antimicrobial compound, starting with its biotechnological
synthesis and ending with its antimicrobial function in mammalian immune
cells.
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1. INTRODUCTION
Itaconic acid (also known as methylene succinic acid) is an organic, unsaturated dicarboxylic
acid that plays an important role in immunity as well as in industrial biotechnology. Itaconic
acid is of high interest for industry because the double bond of its methylene group makes this
metabolite useful for polymer synthesis. The biotechnological production of itaconic acid was
established in the 1960s, and the compound is currently produced by the fungusAspergillus terreus.
However, industrial companies are still interested in optimizing the production process to satisfy
the increasing demand for itaconic acid for widespread applications (47, 72).
In a recent surprising discovery, itaconic acid biosynthesis was found in mammalian immune
cells and has been linked to inflammation (91). Immune cells, such as macrophages and dendritic
cells, are known to undergo a drastic metabolic change during inflammatory processes. However,
themammalian synthesis of itaconic acid could not be explained by a knownmammalianmetabolic
pathway, and up until 2013, no enzymatic reaction for its production had been described (89).
In 2013, the mammalian metabolic pathway for itaconic acid biosynthesis was revealed: In
mammals, itaconic acid is produced by the decarboxylation of cis-aconitic acid, a tricarboxylic acid
(TCA) cycle intermediate, by immune-responsive gene 1 protein (IRG1) encoded by immunore-
sponsive gene 1 (Irg1) (64). It has been known for decades that this gene is highly upregulated in
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CAD: cis-aconitic acid
decarboxylase
mammalian macrophages under proinflammatory conditions, such as bacterial infections. But the
catalytic function of IRG1 protein and the important role of itaconic acid during inflammation
were only recently discovered.
Itaconic acid acts as an endogenously formed antimicrobial compound that contributes, to-
getherwith several other inflammatorymetabolites and cytokines, to an efficient immune response.
However, invading pathogens have developed a defense strategy against itaconic acid, degrading
and detoxifying this antimicrobial compound (63, 81).
Several reviews on itaconic acid production have been published (26, 47, 72, 106), but all lack a
focus on itsmammalian biosynthesis.Thepresent review summarizes the industrial production and
related fungal metabolism of itaconic acid and highlights its antimicrobial role against pathogens
during inflammation. In this context, we provide a broad overview on IRG1 and the metabolism
of itaconic acid in mammalian cells to account for its importance in the emerging concept of
metabolic immunity.
2. ITACONIC ACID BIOSYNTHESIS
2.1. The Beginning of Itaconic Acid Production
In 1836, Baup discovered the formation of an unknown compound during distillation of citric acid
(4). In 1840, Crasso synthesized the same compound by decarboxylation of cis-aconitic acid and
introduced its current name, itaconic acid, which represents an anagram of cis-aconitic acid (98).
Almost 100 years later, in 1931, itaconic acid was found for the first time to be produced in vivo
by the fungus Aspergillus itaconicus, which has been descriptively named thereafter (46). To date,
several other natural producers of itaconic acid were identified, such as Aspergillus terreus (12),
Ustilago zeae (38), and Ustilago maydis and the yeast Candida sp. (93). In 2011, Sugimoto et al. (91)
discovered that mammalian immune cells are also able to synthesize itaconic acid (see Section 5).
2.2. Itaconic Acid Metabolism in A. terreus
Although itaconic acid continued to be of high interest for industrial applications, the exact
metabolic precursor for its biosynthesis inA. terreuswas not clarified for many years. Three differ-
ent pathways were postulated, including its formation from cis-aconitic acid, from citramalic acid,
or from 1,2,3-tricarboxypropane. All of these biosynthetic pathways are based on the catabolism
of sugars to pyruvic acid and acetyl-CoA as potential precursors for itaconic acid synthesis (9).
In 1957, Bentley &Thiessen (5, 6) proposed the formation of itaconic acid from the TCA cycle
intermediate cis-aconitic acid. The authors hypothesized that itaconic acid is produced through a
decarboxylation catalyzed by the enzyme cis-aconitic acid decarboxylase (CAD), which is encoded
by the gene cadA. Later, isotope tracing experiments using labeled carbon substrates confirmed
this proposed pathway (9).
Essential for itaconic acid production is the catalytic activity of aconitase, an enzyme catalyzing
the formation of the precursor cis-aconitic acid from citric acid (42). It has been shown that the
enzymatic activity, as well as the transcriptional level of aconitase, is elevated during itaconic acid
formation (42). Surprisingly, the inhibition of aconitase using the toxic chemical fluoroacetate (31,
110) does not affect itaconic acid production in A. terreus (5).
As a carbon source for itaconic acid production, the fungus takes up glucose from the
extracellular environment and metabolizes it into itaconic acid. The breakdown of one molecule
of glucose leads to two molecules of pyruvic acid: One molecule is further converted to
acetyl-CoA through oxidative decarboxylation catalyzed by pyruvate dehydrogenase, while the
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other molecule is converted in the cytosol to oxaloacetic acid catalyzed by the anaplerotic enzyme
pyruvate carboxylase. In contrast to its mitochondrial location in mammals, pyruvate carboxylase
is present in the cytosol in A. terreus. CO2, which is needed for the carboxylation of pyruvic acid,
could be derived either from cis-aconitic acid decarboxylase or pyruvate dehydrogenase activity.
Oxaloacetic acid is reduced to malic acid, which is transported into the mitochondria where it is
reoxidized to oxaloacetic acid (see Figure 1) (7, 47). In addition to CAD and aconitase, another
enzyme required for itaconic acid production is citrate synthase. This enzyme catalyzes the
condensation of acetyl-CoA and oxaloacetic acid to form citric acid. Aconitase further dehydrates
citric acid to cis-aconitic acid, the direct precursor of itaconic acid. As the last step for itaconic
acid production, CAD decarboxylizes cis-aconitic acid to itaconic acid (see Figure 1).
Citric acid
cis-Aconitic acid
Isocitric acid
α-Ketoglutaric acid
Succinic acid
Fumaric acid
Malic acid
Oxaloacetic acid
CoA-SH
Acetyl-CoA
TCA cycle
Itaconic acid
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Figure 1
Biosynthesis of itaconic acid production and its subcellular localization in Aspergillus terreus. Glucose, as a substrate for itaconic acid
formation, is converted through glycolysis into pyruvic acid in the cytosol. Pyruvic acid enters the tricarboxylic acid (TCA) cycle in the
mitochondria either via acetyl-CoA or malic acid. The TCA cycle intermediate cis-aconitic acid is transported from the mitochondria
into the cytosol, possibly through the citrate-malate antiporter ( green box), and serves as a precursor for itaconic acid production
catalyzed by cis-aconitic acid decarboxylase (CAD). Finally, itaconic acid is further secreted into the medium through an unknown
transport mechanism (blue box). Extracellular metabolites are marked in blue; cytosolic metabolites, green; mitochondrial metabolites,
black; and involved enzymes, red. Abbreviations: FAD, flavin adenine dinucleotide; FADH2, reduced form of flavin adenine
dinucleotide; NADH, reduced form of nicotinamide adenine dinucleotide; NAD+, oxidized form of nicotinamide adenine dinucleotide.
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Acrylic acid: the
simplest unsaturated
carboxylic acid,
consisting of a vinyl
group connected
directly to a carboxylic
terminus
To understand the regulation of itaconic acid production, Bonnarme et al. (9) compared the
regulation of itaconic acid production in A. terreus with that of citric acid production in A. niger.
The authors showed that during itaconic acid synthesis, the concentrations of pyruvic acid, ox-
aloacetic acid, and citric acid were increased. Since the same metabolites also show increased
levels during citric acid production in A. niger, they speculated a similar regulation for itaconic
acid production in A. terreus. Mechanistically, oxaloacetic acid inhibits α-ketoglutarate dehydro-
genase while it stimulates the condensation of acetyl-CoA and oxaloacetic acid to form citric acid,
catalyzed by citrate synthase (9). It is so far not clear whether itaconic acid production is exclusively
initiated by this mechanism or by additional as-yet-unknown regulatory mechanisms, especially
when considering the subcellular compartmentalization of itaconic acid synthesis.
2.3. Subcellular Compartmentalization of Itaconic Acid
Biosynthesis in A. terreus
In A. terreus, CAD is localized in the cytosol, and consequently, this is the location of itaconic
acid production. However, its direct precursor, cis-aconitic acid, is synthesized in mitochondria.
Citrate synthase, the enzyme that catalyzes the condensation of acetyl-CoA and oxaloacetic acid
to form citric acid, is exclusively present in mitochondria. Moreover, the reaction from citric acid
to cis-aconitic acid, catalyzed by aconitase, also operates in mitochondria (42).
As a consequence, a transport of cis-aconitic acid or citric acid from mitochondria into the
cytosol is required (seeFigure 1). Jaklisch et al. (42) postulated that cis-aconitic acid is translocated
from themitochondria into the cytosol via a citrate-malate antiporter.However, the exact transport
mechanism is still unknown, and it is possible that other carrier systems are involved in cis-aconitic
acid translocation (42). To this end, a putative mitochondrial carrier protein that is encoded by a
gene located directly upstream of the cadA gene was identified, supporting the likelihood that this
carrier protein is indeed involved in cis-aconitic acid shuttling into the cytosol (88).
Finally, a secretion mechanism for itaconic acid is required because A. terreus accumulates
itaconic acid in the extracellular environment (88). However, potential transporters involved are
not yet known. Considering that itaconic acid is secreted in large amounts by A. terreus, it can be
hypothesized that the compound is not further metabolized by this fungus and may have other
functions. As we discuss in Section 4, itaconic acid is an antimicrobial compound, and based on
this knowledge, it is possible that A. terreus produces and secretes itaconic acid to combat against
competing microbes.
3. INDUSTRIAL PRODUCTION OF ITACONIC ACID
The discovery of itaconic acid has been of growing interest for industry because of its potential
role as a replacement for crude oil–based products, such as acrylic acid. The chemical structure
of itaconic acid, with its reactive methylene group, enables a self-polymerization to polyitaconic
acid (88). Therefore, itaconic acid is industrially used as a precursor for plastic polymer synthesis
as well as for resins, lattices, and fibers (for reviews, see 26, 72, 106).
Currently, the annual global production capacity of itaconic acid is approximately 40,000 tons,
with one kilogram costing 1.5–2.5 USD (47). To satisfy the increasing demand of itaconic acid
for widespread applications, industrial-scale production of itaconic acid is required. Because dis-
tillation of citric acid leads to low itaconic acid yields, itaconic acid is currently mainly biotechno-
logically produced through a fermentation process by the fungus A. terreus (9, 72).
The first industrial itaconic acid production process was established in the United States in
1945 by Charles Pfizer Co., which owned the patent for fermentative itaconic acid production.
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Subsequently, manufacturers from Europe, China, and Japan followed (106). Currently, A. terreus
is used in batch processes at temperatures around 37◦C, with glucose, or cheaper pretreated starch
materials, as substrates for commercial itaconic acid production. The fermentation process occurs
under phosphate-limiting growth conditions (106) and in an acidic environment (52).
The biosynthetic and process parameters of itaconic acid formation are well described and have
been established since the 1960s; this topic is broad enough for its own review and is not discussed
here. Instead, we refer readers to previously published reviews by Okabe et al. (72), Willke &
Vorlop (106), Klement & Bu¨chs (47), and El-Imam & Du (26).
AlthoughA. terreus produces up to 86 g · l−1 of itaconic acid, industrial companies are interested
in further optimizing the production process. This includes the increase of space-time yield and
final product concentration, as well as the utilization of cheaper substrates to make the process
even more economical (47).
As an example of economization, Bressler & Braun (11) have investigated an itaconic acid
production process in a membrane reactor using citric acid as a precursor, which is about one-
tenth the cost of itaconic acid. In addition to the use of conventional batch processes, production
of itaconic acid was investigated with immobilized A. terreus in continuous processes, which have
been shown to increase spatiotemporal yields (44).
However, efficient itaconic acid production using filamentous fungi has certain drawbacks.
For example, fermentative itaconic acid production by the fungus A. terreus is strictly aerobic
because low oxygen concentrations damage the mycelia and affect fungal metabolism due to low
adenosine triphosphate (ATP) production (34, 106). In addition, oxygen supply is required for the
oxidation of the reduced formof nicotine adenine dinucleotide (NADH) to regenerate the cofactor
NAD+ (oxidized form of NAD). High NADH levels inhibit important enzymes, including citrate
synthase and phosphofructokinase, which are involved in itaconic acid production (47). Thus,
the production process requires continuous aeration and high power input with high stirring
intensities, resulting in increased mechanical stress that damages the mycelia. To overcome this
drawback, an itaconic acid production process in air-lift bioreactors, containing draft tubes instead
of stirrers, was developed to increase production rates (73, 108). Another promising idea is based
on the use of an engineered A. terreus expressing a hemoglobin gene from the aerobic bacterium
Vitreoscilla to reduce oxygen dependency and to increase itaconic acid formation (56).
Because the itaconic acid production process is sensitive to several medium components (106),
media optimization is of high importance. For that purpose, small-scale screenings in scaled-down
models, e.g., microtiter plates, have been developed to circumvent costly optimization procedures
in bioreactors (39).
It has also been reported that itaconic acid itself inhibits the growth of A. terreus and, in turn,
suppresses the formation of itaconic acid. Such product inhibition can be overcome by using
mutant strains that are more resistant to itaconic acid (109). Because itaconic acid does not alter
the gene expression of cadA (43), itaconic acid possibly alters CAD activity. Therefore, more
detailed research on the exact mechanism of itaconic acid feedback inhibition is required.
Another strategy to increase itaconic acid yields is in taking advantage of other host organisms,
such as A. niger, a strain that is known to produce up to 200 g · l−1 citric acid. Due to the lack of a
cis-aconitic acid decarboxylating enzyme, the cadA gene of A. terreus was engineered into A. niger.
However, compared to the citric acid synthesis capacity, very low itaconic acid concentrations
(0.05 g · l−1) were achieved. Only concomitant overexpression of a mitochondrial transporter
(mttA) in combination with a plasma membrane transporter (mfsA) led to a 20-fold increased
yield compared to the overexpression of cadA alone (101). The authors of this article suggest
that MfsA is a membrane transporter required for itaconic acid secretion (for more details on
subcellular compartmentalization of itaconic acid biosynthesis, see Section 2). The optimization
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Glyoxylate shunt:
anabolic pathway that
allows growth on C2
compounds by
bypassing the
decarboxylation steps
of the TCA cycle
ICL: isocitrate lyase
of the fermentation process using the natural itaconic acid producerUstilago maydis only achieved,
with 44.5 g · l−1 of itaconic acid, half of the production of A. terreus (57).
For increasing itaconic acid yields, the kinetic parameters and the low stability of CAD enzyme
need to be considered. To compensate for the low stability of CAD enzyme, strains overproduc-
ing itaconic acid require a high mRNA level of cadA (109). For the same reason, the enzymatic
characterization of fungal CAD is challenging and is one of the reasons why the enzymatic prop-
erties of this enzyme in A. terreus have only been recently described by Dwiarti et al. (25). The
authors showed that the fungal CAD enzyme has a molecular mass of 55 kD and determined
the Michaelis-Menten constant (KM) for the substrate cis-aconitic acid at pH = 6.2 and 37◦C as
KM = 2.45mmol · l−1 (25). Based on the highKM value, CADhas a low affinity to the itaconic acid
precursor cis-aconitic acid, and thus high substrate levels are required to reach maximal itaconic
acid production. Supplementation of cis-aconitic acid into the growth medium in combination
with an engineered A. terreus strain that has the ability to transport cis-aconitic acid from the ex-
tracellular environment into the cytosol could be beneficial in increasing itaconic acid production.
Despite the use of different strategies to optimize itaconic acid yields, none has achieved higher
production rates than fermentation by A. terreus. Therefore, fermentation by this fungus is still
the dominant commercial process used for itaconic acid production. However, the high interest
in process optimization could lead to a future replacement of A. terreus by a different organism as
the main itaconic acid producer (47).
4. ANTIMICROBIAL ACTIVITY OF ITACONIC ACID
4.1. Itaconic Acid Inhibits the Glyoxylate Shunt
Itaconic acid plays an important role as a bioactive compound in living organisms: Itaconic acid
inhibits the glyoxylate shunt essential for many bacteria to survive during infection (59, 75). The
activation of the glyoxylate shunt is a survival strategy of invading pathogens, allowing them
to utilize acetyl-CoA-generating carbon sources such as fatty acids or cholesterol for biomass
production under glucose-limiting conditions (51). As an example, this metabolic mechanism is
required for persistence of the pathogens Salmonella enterica andMycobacterium tuberculosis within
macrophages, but it is not essential for acute-phase infections (28, 51, 61).
The glyoxylate shunt is an anabolic variation of the TCA cycle (see Figure 2). In contrast
to the net decarboxylation of acetyl-CoA in the TCA cycle, the glyoxylate shunt preserves the
carbon atoms of acetyl-CoA by bypassing the two decarboxylation steps. Isocitric acid is converted
to glyoxylic acid and succinic acid, a reaction catalyzed by isocitrate lyase (ICL). Malate synthase
further converts glyoxylic acid and another acetyl-CoA molecule to malic acid (24, 84).
Itaconic acid inhibits ICL, the key enzyme of the glyoxylate shunt, and, in turn, the glyoxylate
shunt itself. It functions as a competitive inhibitor, competing with succinic acid (60), presumably
by binding to the active site of the enzyme. Although ICL and the glyoxylate shunt are present
in many bacteria, archaea, plants, fungi, and protists, there is controversy over whether they
are present in vertebrates (24). Because of its exclusive presence in microbes, this shunt has an
important role as a potential drug target (69).
4.2. Itaconic Acid Inhibits Bacterial Growth
In 2011, Shin et al. (86) detected the presence of itaconic acid in the lung tissue ofM. tuberculosis-
infected mice, but they hypothesized that this metabolite was synthesized by the bacteria and
not by the host. Conversely, Michelucci et al. (64) recently demonstrated that following bacterial
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Glyoxylic
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Acetyl-CoA
Propionyl-CoA
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Acetyl-CoA
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Figure 2
Antimicrobial activity: itaconic acid mode of action on pathogen metabolism. Itaconic acid is an inhibitor of isocitrate lyase, the key
enzyme of the glyoxylate shunt. Because isocitrate lyase has an additional methylisocitrate lyase activity inMycobacterium tuberculosis,
itaconic acid also inhibits this 2-methylcitrate cycle in these bacteria. The inhibition of propionyl-CoA carboxylase by itaconic acid
arrests the citramalate cycle in the proteobacterium Rhodospirillum rubrum. Enzymes inhibited by itaconic acid are in blue type, and
inhibited biochemical pathways are in red.
Phagosome: cellular
compartment formed
by the fusion of the
cell membrane inside
which pathogenic
microorganisms are
killed and digested
infection, mammalian immune cells, such as macrophages, produce large intracellular amounts of
itaconic acid with concentrations around 8 mmol · l−1 (see Section 5). The authors experimentally
demonstrated the antimicrobial activity of itaconic acid and its role during immune defense against
invading pathogens. Supplementation of 25–50 mmol · l−1 itaconic acid to the bacterial growth
medium fully inhibits the growth of the pathogenM. tuberculosis, whereas 10mmol · l−1 is sufficient
to impair the growth of S. enterica (64). The purpose behind these high itaconic acid levels inside
the immune cells is to combat against invading pathogens by inhibiting their ICL activity and,
in turn, their growth. ICL activity is essential for the pathogens Mycobacterium avium and M.
tuberculosis when growing on acetic acid or palmitic acid as carbon sources (40).
From a different point of view, ICL is a persistence factor in Burkholderia pseudomallei. The
inhibition of ICL by itaconic acid switches infections in rats to an acute state. Thus, itaconic acid
“wakes up” pathogens. With this strategy, itaconic acid does not directly inhibit the growth of the
pathogen but rather enables a starting point for a further treatment with antibiotics to inhibit the
pathogens’ growth (102).
In addition to ICL, itaconic acid also inhibits other enzyme functions and, in turn, affects
metabolic pathways, including the 2-methylcitrate cycle (see Figure 2). Invading pathogens, such
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asM. tuberculosis, use cholesterol from the host as a carbon source due to limited glucose availability
in phagosomes (74, 79). During the last step of cholesterol degradation, propionyl-CoA, which is
also the final product of odd-chain fatty acid oxidation, is produced. Since propionyl-CoA is toxic
for the pathogens (8, 99), they detoxify this metabolite to succinic acid and pyruvic acid using the
2-methylcitrate cycle. The first reaction is catalyzed by methylisocitrate lyase (MCL), which is
very similar to ICL (100). In this context, it is intriguing that both ICL isoforms ofM. tuberculosis
also exhibitMCL activity and are essential for propionyl-CoA detoxification in these bacteria (68).
Indeed, we demonstrated that itaconic acid inhibits the growth of M. tuberculosis within
macrophages by interfering with the above-mentioned pathways: first, inhibition of MCL ac-
tivity leads to the inhibition of propionic acid detoxification; second, the inhibition of ICL leads
to the inability of the bacteria to generate biomass through the glyoxylate shunt (see Figure 2).
Itaconic acid exhibits a dual inhibition on bacterial enzymes, thus playing a prominent role as an
endogenous antimicrobial compound (64).
4.3. Itaconic Acid Inhibits the Citramalate Cycle
Interestingly, itaconic acid also inhibits propionyl-CoA carboxylase, an enzyme that carboxylizes
propionyl-CoA to methylmalonyl-CoA in the citramalate cycle (see Figure 2) (8). This cycle
is an anaplerotic pathway proposed for the proteobacterium Rhodospirillum rubrum, which lacks
ICL activity. The inhibition of propionyl-CoA carboxylase by itaconic acid leads to an inhibition
of acetic acid and propionic acid assimilation in cell extracts of this bacterium. However, cell
growth was not affected by supplementation of itaconic acid in the medium and, based on these
observations, Berg et al. (8) suspected that the bacterium is either able to secrete itaconic acid or
to detoxify it. Taken together, these findings demonstrate that itaconic acid can inhibit metabolic
pathways in pathogens lacking the glyoxylate shunt and, thus, also ICL activity (see Figure 2).
4.4. Bacteria Detoxify Itaconic Acid
Recently, Sasikaran et al. (81) discovered thatmany pathogens have developed defensemechanisms
to detoxify itaconic acid, including Yersinia pestis and Pseudomonas aeruginosa. The degradation
and detoxification of itaconic acid in these invading pathogens is catalyzed by three recently
identified genes: itaconate coenzyme A transferase (Ict), itaconyl CoA hydratase (Ich), and (S)-
citramalyl-CoA lyase (Ccl ). The combined action of these enzymes finally degrades itaconic acid
to acetyl-CoA and pyruvic acid. All of these enzymes are essential for the survival of Yersinia
pestis within host organisms and were described long before their importance for itaconic acid
degradation was elucidated. Thus, the three-gene cluster was named “required for intracellular
proliferation” (ripABC) (63). This pathway is in line with the previously reported degradation
pathway in mammalian mitochondria (see Section 5) (2, 104) and with the previous observations
of Berg et al. (8). As discussed in Section 4.3, the authors observed that itaconic acid does not
affect the growth of Rhodospirillum rubrum, although it inhibits the citramalate cycle. However,
they could not discover the bacterial itaconic acid degradation pathway and the involved enzymes.
The production of itaconic acid in macrophages and subsequent pathogen adaptation to this
antimicrobial compound are highlighted in Figure 3.
Interestingly, homologues of this three-gene cluster are also present in many other pathogens,
including Yersinia pseudotuberculosis, S. enterica, Burkholderia mallei, Mycoplasma synoviae, and Le-
gionella longbeachae. Thus, these pathogenic bacteria possibly also exhibit the ability to detoxify and
metabolize itaconic acid. In fact, it has been shown that Salmonella and Pseudomonas are able to take
up itaconic acid from the medium and to incorporate carbon atoms derived from this metabolite
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Mitochondrion
Cytosol
Phagosome
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TCA
Ccl
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Ict
Itaconic acid
Pyruvic acid
Acetyl-CoA
Itaconic acid
Citramalyl-CoA
Itaconyl-CoA
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Figure 3
Production of itaconic acid in macrophages and adaptation of pathogens. Under inflammatory conditions,
macrophages produce itaconic acid, catalyzed by CAD/IRG1. It might then be further transported from the
mitochondrion into the phagosome and further taken up by invading pathogens through an as-yet-unknown
transport mechanism. Some invading pathogens are able to detoxify itaconic acid by degrading this
antimicrobial compound to pyruvic acid and acetyl-CoA. Abbreviations: CAD/IRG1, cis-aconitic acid
decarboxylase/immune-responsive gene 1 protein; Ccl, (S)-citramalyl-CoA lyase; Ich, itaconyl CoA hydratase;
Ict, itaconate coenzyme A transferase; TCA, tricarboxylic acid.
TLR: Toll-like
receptor
LPS:
lipopolysaccharide, an
endotoxin of
Gram-negative
bacteria
(58). Since the itaconic acid degradation pathway is present inmany bacteria, and it is an important
persistence factor for pathogen survival inside macrophages, it represents a promising target for
new antimicrobial drugs (81).
5. ITACONIC ACID AND MAMMALIAN METABOLISM
5.1. The Discovery of Itaconic Acid and CAD Activity in Mammalian Cells
The innate immune system is the first line of defense during infections. Cells of the innate immune
system recognize pathogen-associated molecular patterns via pattern-recognition receptors, in-
cluding Toll-like receptors (TLRs), which are present on themembrane and in the cytosol. Under
resting conditions, cells of the innate immune system are immunologically inactive; however, upon
recognition of foreign material, such as the bacterial endotoxin lipopolysaccharide (LPS), these
cells have the ability to respond rapidly. To clear the infection, immune cells produce a wide array
of mediators, including cytokines and chemokines, as well as antimicrobial metabolites.
To identify metabolites that are produced during the immune response, Sugimoto and col-
leagues (91) profiled the extracellular metabolites of LPS-activated macrophages. In this context,
they discovered itaconic acid in the extracellular environment (91), but did not discuss its biolog-
ical relevance. Only shortly later, high concentrations of itaconic acid in activated macrophages
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mammalian CAD
(cis-aconitic acid
decarboxylase)
previously known as
immune-responsive
gene 1 protein
PBMC: peripheral
blood mononuclear
cell
were described by Strelko et al. (89), who first highlighted itaconic acid as a novel mammalian
metabolite that most likely plays a role in macrophages during immune responses.
Following the discovery of itaconic acid in mammalian immune cells, its biosynthesis pathway
was revealed using stable isotope-assisted metabolomics (64, 89). Incubation of LPS-activated
macrophages with uniformly labeled [U-13C6]glucose revealed that mammalian cells produce ita-
conic acid through decarboxylation of the TCA cycle intermediate cis-aconitic acid (64, 89), which
is the same metabolic pathway as described for A. terreus (see Section 2). Two years later, we iden-
tified the enzyme catalyzing this decarboxylation: through a sequence homology search for As-
pergillusCAD,we found themammalian IRG1as theCADhomologue inmammals (64).Aspergillus
CAD shows a 23% amino acid sequence identity to murine IRG1 and 25% identity to human
IRG1. Murine and human IRG1 protein amino acid sequences are 84% identical. Furthermore,
enzymatic assays with purified mammalian IRG1 and cis-aconitic acid as substrate showed itaconic
acid production, finally confirming the CAD activity of IRG1 (64). Following the discovery of its
enzymatic activity, IRG1 protein was recently renamed to CAD (UniProtKB/Swiss-Prot: mouse
CAD-accession number P54987; human CAD-accession number A6NK06). To avoid confusion
in the nomenclature of CAD proteins between Aspergillus and mammals, we refer to mammalian
IRG1 protein as CAD/IRG1.
The CAD/IRG1 protein is encoded by immunoresponsive gene 1 (IRG1); its sequence has
been mapped to mouse chromosome 14 (53), and its human homologue has been located to
chromosome 13q22.3. Interestingly, the predicted mRNA sequence of the human IRG1 gene has
been updated several times in the past few years (107), and we have confirmed that only the most
recently published sequence (RefSeq NM_001258406.1) codes for a functional CAD/IRG1 (64).
5.2. IRG1 Gene Expression in Mammalian Cells
In 1995, Irg1 transcript was isolated for the first time from a cDNA library prepared from
endotoxin-stimulated murine macrophages (53). Later, Irg1 upregulation was observed in murine
macrophages infected with Mycobacteria (3, 85) or S. enterica (64) as well as in LPS-stimulated
bone marrow–derived dendritic cells (41). IRG1 expression has also been detected in human fetal
peripheral blood mononuclear cells (PBMCs) and LPS-stimulated adult PBMCs (107) as well as
in endotoxin-activated PBMC-derived macrophages (64). In addition, IRG1 is highly upregulated
in PBMCs of septic patients (55).
Besides peripheral immune cells, Irg1 expression has also been observed in murine microglial
cells, which aremacrophage analogues of the central nervous system. In these cells, Irg1 expression
is upregulated in vivo after infection with Toxoplasma gondii (54) and in vitro after LPS stimulation
(97).
Irg1 expression has been detected in the lung tissue of mice during the early phase of influenza
A virus infection (77) and in chickens infected with Marek’s disease (87). Given the enzymatic
function of CAD/IRG1 to produce the antimicrobial compound itaconic acid, it is intriguing that
its expression can also be induced during viral infections, since viruses do not possess a proper
metabolism toward which itaconic acid could potentially interfere. The observed IRG1 induction
during viral infections suggests an additional function of CAD/IRG1, independent of itaconic acid
production.
In a recent study, Irg1 expression was increased after infection with neurotropic viruses. In
this analysis, Irg1 expression was unexpectedly detected in cells that do not belong to the immune
system, namely in granule cell neurons of the cerebellum and in cortical neurons from the cerebral
cortex.Different Irg1 expression levels in these two types of neurons have been linked to differential
susceptibility to viral infections (17).
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ROS: reactive oxygen
species
Finally, independently from pathogenic conditions such as bacterial or viral infections, an
upregulation of Irg1 expression has been detected in the early events leading to implantation in
the pregnant uterus (15, 16, 96). In this phase, a high level of inflammatory cytokines is secreted
by the endometrial cells as well as by cells of the immune system, which are recruited to the site
of implantation (66). Thus, it seems that Irg1 expression contributes to this immune response,
probably producing high levels of itaconic acid as an antimicrobial compound.
Taken together, these results demonstrate that IRG1 expression is related to infectious and
inflammatory conditions and point toward the importance of CAD/IRG1 contributing to the
immune response.
5.3. IRG1 Posttranscriptional Stability and CAD/IRG1 Regulation
The stability of Irg1mRNA is dependent on the type of infection. An analysis of posttranscriptional
regulation revealed that Irg1mRNA stability was increased in LPS-stimulated macrophages when
compared toMycobacterium avium infections (3). The control ofmRNA stability is a crucial point of
gene expression regulation. A common element responsible for the modulation of mRNA decay is
the adenine- and uracil- (AU)-rich element in the 3′ untranslated region (UTR) of target mRNAs
(13, 82). With its AU-rich elements in the 3′-UTR, Irg1 expression can be modulated by this
mechanism (3). Interestingly, inhibitionof eukaryotic protein synthesis by cycloheximide increased
Irg1 mRNA stability in M. avium–infected macrophages. This could indicate the presence of as-
yet-unknown factors destabilizing Irg1 mRNA (3).
At the protein level, sequence analysis identified putative cyclic adenosine monophosphate-
dependent phosphorylation sites and many putative protein kinase C phosphorylation sites near
the C-terminus. Thus, CAD/IRG1 protein may be regulated at this level (53). However, detailed
investigations of CAD/IRG1 protein regulation at the phosphorylation level are still pending.
5.4. Subcellular Localization of Mammalian CAD/IRG1
In contrast to its cytoplasmic localization inAspergillus (see Section 2), mammalianCAD/IRG1 has
been shown to colocalize withMitoTracker Green FM, a fluorescent compound that accumulates
specifically in mitochondria (22). These observations were validated by cell fractionation experi-
ments, in which CAD/IRG1 was found only in stimulated cells, and the vast majority was in the
mitochondrial fraction. This is of special interest because CAD/IRG1 does not contain a known
mitochondrial-targeting peptide (22). On the other hand, it has been shown that CAD/IRG1 con-
tains consensus sequences for glycosaminoglycan (GAG attachment site), a sequence motif that
is characteristic for many secreted cytokines and growth factors (94). Since CAD/IRG1 contains
the GAG motif, it may function similarly to a cytokine and be consequently secreted (53). In
favor of this hypothesis, a recent study that analyzed the secretome of immune cells revealed that
mammalian CAD is among 775 detected proteins that were released by macrophages upon TLR4
induction (62). However, because highly sensitive measurements were used in this study, proteins
that originate from leaking or dying cells could also have been identified. We could not detect
CAD/IRG1 in the medium of LPS-activated macrophages by Western blot (unpublished data).
In support of the mitochondrial localization of CAD/IRG1, further studies have recently
suggested additional functions of this protein linked to mitochondria. Investigators using
zebrafish (Danio rerio) as an animal model have demonstrated that CAD/IRG1 augments bac-
tericidal activity of macrophages by regulating β-oxidation-dependent mitochondrial reactive
oxygen species (ROS) production (35). Fatty acid β-oxidation is a multistep process by which fatty
acids are broken down to acetyl-CoA to produce energy through the TCA cycle and oxidative
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phosphorylation. As a by-product of oxidative phosphorylation, mitochondria produce superox-
ide, a ROS, through electrons leaking from the electron transport chain (83). Hall et al. (35)
showed that in zebrafish, fatty acid supplementation can enhance mitochondrial ROS production
in response to infection in an irg1-dependent manner. In a subsequent study by the same group,
again in a zebrafish model, a similar mechanism has been described in epidermal cells. These
cells utilize fatty acid β-oxidation to participate in the immune response during cutaneous inflam-
mation. This mechanism also requires the activity of irg1-like, a second zebrafish homologue of
the mammalian Irg1 (36). ROS species can function as signaling molecules to regulate the tran-
scription and activity of various inflammatory mediators, including matrix metalloproteinases (70,
92), which contribute to macrophage recruitment during inflammatory processes of the skin (36).
However, the mechanisms discovered in these studies have not yet been confirmed in mammalian
cells.
Due to the importance of CAD/IRG1 in the immune–metabolism cross talk, it is plausible to
think that further functions will be elucidated soon. At present, it is not known if these functions
are accomplished directly by CAD/IRG1 or if in reality they are mediated by its product, itaconic
acid.
5.5. Itaconic Acid Secretion and Metabolism in Mammalian Cells
Although in the previous sections we focused on itaconic acid biosynthesis, its secretion and
degradation in mammalian cells have also been the subject of a few studies.
At present, the ability of activated macrophages to secrete itaconic acid has been reported
(90, 91). In line with this finding, itaconic acid has been found to be more abundant in the
serum of pregnant women who subsequently developed diabetes when compared to controls with
uncomplicated pregnancies. Therefore, the presence of itaconic acid may demonstrate a potential
role of inflammation in early pregnancy in the development of gestational diabetes mellitus (21).
However, at present this is the only study that describes itaconic acid as a potential serological
biomarker for inflammation.
Once itaconic acid is released, itaconic acid degradation may occur in cell types other than
macrophages. It has been known for a long time that mammals are able to metabolize itaconic
acid in liver cells. This itaconic acid degradation pathway in soluble extracts of rat and guinea pig
liver mitochondria was described in the 1960s (2, 104) following the observation that when fed to
dogs, only 24% of supplied itaconic acid could be found in their urine (27). Liver cells express a
sodium-dependent dicarboxylate transporter (14, 45), by which itaconic acid may be concentrated
and subsequently degraded.
In this mammalian degradation pathway, itaconic acid is first activated to the correspond-
ing CoA ester to itaconyl-CoA by succinyl-CoA synthetase. Subsequently, similar to bacteria
(see Section 4), itaconyl-CoA is hydrated to (S)-citramalyl-CoA, which is then cleaved by (S)-
citramalyl-CoA lyase into acetyl-CoA and pyruvic acid (2, 20). Interestingly, recent studies have
identified a human gene annotated as CitE-like protein (CLYBL-HUMAN) that possesses (S)-
citramalyl-CoA lyase activity (81).
5.6. Itaconic Acid Affects Energy Metabolism
Itaconic acid inhibits rat liver phosphofructokinase 2, a key regulator of the glycolytic pathway.
Phosphofructokinase 2catalyzes the phosphorylation of fructose-6-phosphate to fructose-2,6-
bisphosphate (80). Fructose-2,6-bisphosphate in turn allosterically activates phosphofructokinase
1, which catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate.Due
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to the inhibition of the glycolytic pathway, it has been shown that itaconic acid suppresses the
synthesis of fatty acids from glucose. In rats, an itaconic acid–enriched diet leads to a reduced
visceral fat accumulation; therefore, itaconic acid could play a role in controlling obesity (80).
In addition to the inhibition of glycolysis, itaconic acid affects the TCA cycle. Like other TCA
cycle intermediates, such asmalic acid and oxaloacetic acid, itaconic acid has an inhibitory effect on
succinate dehydrogenase (SDH) (1, 10, 23).This enzyme complex binds to the innermitochondrial
membrane and oxidizes succinic acid to fumaric acid as part of the TCA cycle and in turn reduces
flavin adenine dinucleotide (FAD) to FADH2, which feeds into the electron transport chain.
Inhibition of SDH by itaconic acid should lead to accumulation of succinic acid in mitochondria.
Indeed, recent findings show that LPS strongly increases succinic acid levels (95). On the other
hand, several other causes, apart from SDH inhibition, could contribute to the accumulation of
succinic acid. In a recent review by Mills & O’Neill (65), two other possible sources are discussed.
The first source is an increased glutamine uptake in LPS-activated macrophages and subsequent
anaplerosis of α-ketoglutaric acid into the TCA cycle, which may lead to increased succinic acid
production. The second source is based on γ-aminobutyric acid (GABA), the production of which
is induced by LPS. GABA can then be a substrate for succinic acid synthesis via transamination to
succinic semialdehyde and subsequent oxidation (65).
6. THE EMERGING CONCEPT OF METABOLIC IMMUNITY:
THE INTERPLAY AMONG IMMUNITY, INFLAMMATION,
AND METABOLISM
6.1. Metabolic Shifts in Immune Cells During Inflammation
Metabolic adaptationof immune cells duringhealth anddisease states is a topic that is broad enough
for its own review (30, 71, 76). Here, we concisely describe the basic concepts, which illustrate how
specific inflammatory processes and immune responses are characterized by significant changes in
cellular metabolic activities (49). Emerging evidence highlights the important interplay between
different inflammatory environments and the resulting metabolic shift of the immune cells. As
an example, after exposure to TLR agonists, macrophages and dendritic cells switch to aerobic
glycolysis in addition to oxidative phosphorylation (50, 78), similar to theWarburg effect displayed
by cancer cells (103).
In their review, O’Neill & Hardie (71) describe macrophage metabolic changes in detail, stat-
ing that increased ROS production in classically activated (M1) cells (33, 67) occurs partly because
of the attenuation of oxidative phosphorylation, whereas increased glycolytic flux is needed to
maintain ATP levels for biosynthesis. As such, the production of nicotinamide adenine dinucleo-
tide phosphate (NADPH) by the pentose phosphate pathway is favored. NADPH is the electron
donor for NADPH oxidase, finally transferring electrons to molecular oxygen, thus producing the
superoxide anion, a potent ROS species. Furthermore, mitochondria are recruited to phagolyso-
somes in a TNF receptor-associated factor 6 (TRAF6)-dependent fashion and produce ROS that
are important for killing phagocytosed bacteria (see Section 5) (76, 105).
Conversely, alternatively activated (M2) macrophages (32) generate ATP mainly through ox-
idative phosphorylation in mitochondria. Since the electron transport is in this case not impaired,
less ROS is leaking from the respiratory chain. This reflects the role of M2 macrophages in
longer-term processes, such as tissue repair and antiparasitic effects (29, 71).
Modulations of particular metabolic pathways are able to influence and alter the acquisition of
specific phenotypes. Recently, Choi and colleagues (18) demonstrated that inhibition of NADPH
oxidase switchedmicroglial activation, in response to an inflammatory challenge, from a classical to
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NO: nitric oxide
IFN-γ: interferon
gamma, a cytokine
IL-1β: interleukin-1
beta, a cytokine
an alternative state. Another example is the carbohydrate kinase-like protein (CARKL), which cat-
alyzes the conversion of sedoheptulose into sedoheptulose-7-phosphate (37). CARKL-dependent
metabolic reprogramming is required for proper M1 and M2 macrophage polarization.
6.2. Metabolites as Antimicrobial Effectors and Inflammatory Signals
The identification of metabolites playing an active role in the host immune response is a growing
field of research. In the past, nitric oxide (NO), oxygen ions, and peroxides have been shown to
exhibit antimicrobial properties, such as damaging microbial DNA. The essential substrate that
drives NO production is the amino acid arginine, an intermediate of the urea cycle. The inducible
nitric oxide synthase (iNOS) is activated by proinflammatory stimuli, such as interferon gamma
(IFN-γ) or LPS, and catalyzes NO production from arginine, NADPH, and molecular oxygen
(48). On the other hand, arginase is induced in alternatively activated cells, catalyzing arginine
conversion into ornithine and subsequently into proline or polyamines, such as spermidin and
spermin (19). Thus, arginine is a crucial amino acid that is differentially metabolized depending
on the inflammatory environment (see Figure 4).
In contrast to NO or ROS, which act in a broad and unspecific way, itaconic acid has been
shown to specifically and selectively act as an antimicrobial effector. Itaconic acid specifically
inhibits ICL, the first enzyme of the glyoxylate shunt, an essential pathway for the survival of
various bacteria during infection (see Section 4). In a similar context, it has recently been unveiled
that increased levels of succinic acid following LPS exposure enhance interleukin-1β (IL-1β)
production through the stabilization of hypoxia-inducible factor 1 (95). Importantly, succinic acid
is therefore acting as an inflammatory signal in activated macrophages.
Taken together, these observations highlight that itaconic acid, differently from ROS and
NO, acts as a specific antimicrobial metabolite that is generated by central carbon metabolism.
Additionally, the tight cross talk between metabolism and the innate immune system through,
for example, succinic acid accumulation is emphasized (see Figure 4). These recent findings are
pointing toward a new, or at least revisited, field of research that we call metabolic immunity.
7. CONCLUSION AND FUTURE DIRECTIONS
InFigure 5, we highlight the history of itaconic acid, from its first discovery in 1836 to its detection
as an endogenous mammalian antimicrobial compound in 2013. The discovery of its biosynthesis
by the mammalian CAD/IRG1 enzyme has raised several questions on this newly characterized
enzymatic reaction:
1. Industrial companies are highly interested in the optimization of itaconic acid produc-
tion processes. Can the recently discovered mammalian CAD homologue outperform
the classical fungal CAD itaconic acid production? Do kinetic parameters of the mam-
malian CAD/IRG1 differ from those of the fungal CAD and exhibit a higher affinity to its
substrate?
2. Although the mammalian itaconic acid biosynthesis pathway has been recently revealed (64,
89), the relations of host and pathogen, including mammalian CAD/IRG1 and itaconic
acid compartmentalization, as well as potential transport mechanism, are not yet under-
stood. Since itaconic acid is produced in mitochondria in mammals, how is this metabolite
transported into the phagosome and further taken up by invading pathogens?
3. Itaconic acid functions as an inhibitor of various enzymes, including ICL and SDH. As
a result of this metabolic intervention, does itaconic acid formation under inflammatory
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conditions lead to the accumulation of the TCA cycle intermediate succinic acid and induce
further regulatory events?
In conclusion, the discovery of the surprising role of itaconic acid as an immune-supportive
metabolite offers new intervention points for targeting infectious diseases. Itaconic acid synthesis
is the first evidence of a highly specific mechanism disrupting microbial metabolism by immune
cells. Furthermore, the enzymatic function ofmammalianCAD/IRG1has the potential to increase
production yields in biotechnological processes.
Aspartic acid
Citrulline
Arginine
Ornithine
Urea
Nitric oxide
iNOS
Urea cycle
Fumaric
acid
TCA cycle
Succinic acid
Malic acid
Citric acid
Mitochondrion
Glycolysis
ARG1
Glucose
Itaconic acid
CAD/IRG1
Pyruvic acid
NADPH oxidase
Lactic acid
ROS
Immunity-related metabolism
Immune-modulated metabolic enzymes
Antimicrobial or antiviral metabolites
Metabolites modulating immune responses 
Carbamoyl
phosphate
Arginino-succinic
acid
Glucose-6-phosphate
Fructose-6-phosphate
Fructose-1,6-bisphosphate
2NADP+
2O2 O2–
•
Pentose phosphate
pathway
Ribulose-5-
phosphate
2NADPH
Acetyl-CoA
cis-Aconitic acid
Isocitric acid
α-Ketoglutaric acid
Succinyl-CoA
Fumaric acid
Oxaloacetic acid
Mitochondrion
Figure 4
Selected examples of metabolic pathways and enzymes modulated under inflammatory conditions in mouse macrophages. Regulated
enzymes (in red), metabolites possessing antimicrobial properties (in green), and metabolites known to play an active role in immune
responses (in blue) are highlighted. Abbreviations: ARG1, arginase 1; CAD, cis-aconitic acid decarboxylase; iNOS, inducible nitric
oxide synthase; IRG1, immune-responsive gene 1 protein; NADPH, nicotinamide adenine dinucleotide phosphate; ROS, reactive
oxygen species; TCA, tricarboxylic acid.
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SUMMARY POINTS
1. Itaconic acid is biotechnologically produced by the fungus Aspergillus terreus and of high
interest to industry for its use in polymer synthesis.
2. Itaconic acid is produced by the decarboxylation of the TCA cycle intermediate cis-
aconitic acid catalyzed by CAD/IRG1.
3. Itaconic acid plays an important role during inflammation and acts as an endogenously
produced antimicrobial compound against pathogens.
4. Itaconic acid can inhibit microbial growth by interfering with enzymes of central
metabolism, including the glyoxylate shunt, 2-methylcitrate cycle, and the TCA cycle.
5. Invading pathogens have developed a defense strategy to degrade and detoxify itaconic
acid.
6. Itaconic acid acts as a specific antimicrobial metabolite that supports the cellular
metabolic immune response.
DISCLOSURE STATEMENT
The authors are not aware of any affiliations, memberships, funding, or financial holdings that
might be perceived as affecting the objectivity of this review.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Alex Skupin, Dr. Andre´ Wegner, Daniel Weindl, and Sean
Sapcariu for their insightful comments on the manuscript. This work was supported by the Fonds
National de la Recherche, Luxembourg (ATTRACT A10/03).
LITERATURE CITED
1. AckermannWW, Potter VR. 1949. Enzyme inhibition in relation to chemotherapy. Proc. Soc. Exp. Biol.
Med. 72(1):1–9
2. Adler J, Wang S-F, Lardy HA. 1957. The metabolism of itaconic acid by liver mitochondria. J. Biol.
Chem. 229(2):865–79
3. Basler T, Jeckstadt S, Valentin-Weigand P, Goethe R. 2006. Mycobacterium paratuberculosis, Mycobac-
terium smegmatis, and lipopolysaccharide induce different transcriptional and post-transcriptional regu-
lation of the IRG1 gene in murine macrophages. J. Leukoc. Biol. 79(3):628–38
4. Baup S. 1836. Ueber eine neue pyrogen-citronensa¨ure, und u¨ber benennung der pyrogen-sa¨uren
u¨berhaupt. Ann. Pharm. 19(1):29–38
5. Bentley R, Thiessen CP. 1957. Biosynthesis of itaconic acid in Aspergillus terreus. III. The properties and
reaction mechanism of cis-aconitic acid decarboxylase. J. Biol. Chem. 226:703–20
6. Bentley R, Thiessen CP. 1957. Biosynthesis of itaconic acid in Aspergillus terreus. I. Tracer studies with
C14-labeled substrates. J. Biol. Chem. 226(2):673–87
7. Bercovitz A, Peleg Y, Battat E, Rokem JS, Goldberg I. 1990. Localization of pyruvate carboxylase in
organic acid-producing Aspergillus strains. Appl. Environ. Microbiol. 56(6):1594–97
8. Berg IA, Filatova LV, Ivanovsky RN. 2002. Inhibition of acetate and propionate assimilation by itaconate
via propionyl-CoA carboxylase in isocitrate lyase-negative purple bacterium Rhodospirillum rubrum.
FEMS Microbiol. Lett. 216(1):49–54
12.18 Cordes · Michelucci · Hiller
Changes may still occur before final publication online and in print
An
nu
. R
ev
. N
utr
. 2
01
5.3
5. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y C
op
yri
gh
t C
lea
ran
ce
 C
en
ter
 on
 05
/18
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
NU35CH12-Hiller ARI 4 May 2015 15:10
9. Bonnarme P, Gillet B, Sepulchre AM, Role C, Beloeil JC, Ducrocq C. 1995. Itaconate biosynthesis in
Aspergillus terreus. J. Bacteriol. 177(12):3573–78
10. Booth AN, Taylor J, Wilson RH, Deeds F. 1952. The inhibitory effects of itaconic acid in vitro and in
vivo. J. Biol. Chem. 195(2):697–702
11. BresslerE, BraunS. 2000.Conversion of citric acid to itaconic acid in a novel liquidmembrane bioreactor.
J. Chem. Technol. Biotechnol. 75(1):66–72
12. CalamCT,Oxford AE, RaistrickH. 1939. Studies in the biochemistry of micro-organisms: itaconic acid,
a metabolic product of a strain of Aspergillus terreus Thom. Biochem. J. 33(9):1488–95
13. Chen CY, Shyu AB. 1995. AU-rich elements: characterization and importance in mRNA degradation.
Trends Biochem. Sci. 20(11):465–70
14. Chen X, Tsukaguchi H, Chen XZ, Berger UV, Hediger MA. 1999. Molecular and functional analysis
of SDCT, a novel rat sodium-dependent dicarboxylate transporter. J. Clin. Invest. 103(8):1159–68
15. Cheng J, Che N, Li H, Ma K, Wu S, et al. 2013. Extraction, derivatization, and determination of
metabolome in human macrophages. J. Sep. Sci. 36(8):1418–28
16. Cheon Y-P, Xu X, Bagchi MK, Bagchi IC. 2003. Immune-responsive gene 1 is a novel target of proges-
terone receptor and plays a critical role during implantation in the mouse. Endocrinology 144(12):5623–
30
17. Cho H, Proll SC, Szretter KJ, Katze MG, Gale M, Diamond MS. 2013. Differential innate immune
response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-
stranded RNA viruses. Nat. Med. 19(4):458–64
18. Choi S-H, Aid S, KimH-W, Jackson SH, Bosetti F. 2012. Inhibition ofNADPHoxidase promotes alter-
native and anti-inflammatorymicroglial activation during neuroinflammation. J. Neurochem. 120(2):292–
301
19. Classen A, Lloberas J, Celada A. 2009. Macrophage activation: classical versus alternative.Methods Mol.
Biol. 531:29–43
20. Cooper RA, Kornberg HL. 1964. The utilization of itaconate by Pseudomonas sp. Biochem. J. 91(1):82–
91
21. de Seymour JV, Conlon CA, Sulek K, Villas Boˆas SG, McCowan LME, et al. 2014. Early pregnancy
metabolite profiling discovers a potential biomarker for the subsequent development of gestational
diabetes mellitus. Acta Diabetol. 51(5):887–90
22. Degrandi D, Hoffmann R, Beuter-Gunia C, Pfeffer K. 2009. The proinflammatory cytokine-induced
IRG1 protein associates with mitochondria. J. Interferon Cytokine Res. 29(1):55–67
23. Dervartanian DV, Veeger C. 1964. Studies on succinate dehydrogenase. I. Spectral properties of the pu-
rified enzyme and formation of enzyme-competitive inhibitor complexes. Biochim. Biophys. Acta 92:233–
47
24. Dunn MF, Ramı´rez-Trujillo JA, Herna´ndez-Lucas I. 2009. Major roles of isocitrate lyase and malate
synthase in bacterial and fungal pathogenesis.Microbiology 155(Part 10):3166–75
25. Dwiarti L, Yamane K, Yamatani H, Kahar P, Okabe M. 2002. Purification and characterization of
cis-aconitic acid decarboxylase from Aspergillus terreus TN484-M1. J. Biosci. Bioeng. 94(1):29–33
26. El-Imam AA, Du C. 2014. Fermentative itaconic acid production. J. Biodivers. Bioprospect. Dev. 1(1):1–
8
27. Emmrich R. 1939. Stoffwechselversuche mit einigen methylierten niedermolekularen dicarbonsa¨uren.
Hoppe-Seyler’s Zeitschrift fu¨r Physiol. Chemie 261(1–2):61–70
28. Fang FC, Libby SJ, Castor ME, Fung AM. 2005. Isocitrate lyase (acea) is required for Salmonella persis-
tence but not for acute lethal infection in mice. Infect. Immun. 73(4):2547–49
29. Ghassabeh GH, De Baetselier P, Brys L, Noe¨l W, Van Ginderachter JA, et al. 2006. Identification
of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different
pathologic conditions. Blood 108(2):575–83
30. Ghesquie`re B, Wong BW, Kuchnio A, Carmeliet P. 2014. Metabolism of stromal and immune cells in
health and disease. Nature 511(7508):167–76
31. Goncharov NV, Jenkins RO, Radilov AS. 2006. Toxicology of fluoroacetate: a review, with possible
directions for therapy research. J. Appl. Toxicol. 26(2):148–61
www.annualreviews.org • Itaconic Acid as a Mammalian Antimicrobial Metabolite 12.19
Changes may still occur before final publication online and in print
An
nu
. R
ev
. N
utr
. 2
01
5.3
5. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y C
op
yri
gh
t C
lea
ran
ce
 C
en
ter
 on
 05
/18
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
NU35CH12-Hiller ARI 4 May 2015 15:10
32. Gordon S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1):23–35
33. Gordon S, Martinez FO. 2010. Alternative activation of macrophages: mechanism and functions. Immu-
nity 32(5):593–604
34. Gyamerah MH. 1995. Oxygen requirement and energy relations of itaconic acid fermentation by As-
pergillus terreusNRRL 1960. Appl. Microbiol. Biotechnol. 44(1–2):20–26
35. Hall CJ, Boyle RH, Astin JW, Flores MV, Oehlers SH, et al. 2013. Immunoresponsive gene 1 augments
bactericidal activity of macrophage-lineage cells by regulating β-oxidation-dependent mitochondrial
ROS production. Cell Metab. 18(2):265–78
36. Hall CJ, Boyle RH, Sun X, Wicker SM, Misa JP, et al. 2014. Epidermal cells help coordinate leukocyte
migration during inflammation through fatty acid-fuelled matrix metalloproteinase production. Nat.
Commun. 5:3880
37. Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, et al. 2012. The sedoheptulose kinase CARKL
directs macrophage polarization through control of glucose metabolism. Cell Metab. 15(6):813–26
38. Haskins RHR, Thorn JA, Boothroyd B. 1955. Biochemistry of the Ustilaginales. XI. Metabolic products
of Ustilago zeae in submerged culture. Can. J. Microbiol. 1(9):749–56
39. Hevekerl A,KuenzA,VorlopK-D. 2014. Filamentous fungi inmicrotiter plates—an easyway to optimize
itaconic acid production with Aspergillus terreus. Appl. Microbiol. Biotechnol. 98(16):6983–89
40. Ho¨ner zu Bentrup K, Miczak A, Swenson DL, Russell DG. 1999. Characterization of activity and
expression of isocitrate lyase in mycobacterium avium and mycobacterium tuberculosis. J. Bacteriol.
181(23):7161–67
41. Hoshino K, Kaisho T, Iwabe T, Takeuchi O, Akira S. 2002. Differential involvement of IFN-β in
toll-like receptor-stimulated dendritic cell activation. Int. Immunol. 14(10):1225–31
42. Jaklitsch WM, Kubicek CP, Scrutton MC. 1991. The subcellular organization of itaconate biosynthesis
in Aspergillus terreus. J. Gen. Microbiol. 137(3):533–39
43. Kanamasa S, Dwiarti L, Okabe M, Park EY. 2008. Cloning and functional characterization of the cis-
aconitic acid decarboxylase (CAD) gene from Aspergillus terreus. Appl. Microbiol. Biotechnol. 80(2):223–
29
44. KautolaH, RymowiczW,Linko Y-Y, Linko P. 1991. Itaconic acid production by immobilizedAspergillus
terreus with varied metal additions. Appl. Microbiol. Biotechnol. 35(2):154–58
45. Kekuda R, Wang H, Huang W, Pajor AM, Leibach FH, et al. 1999. Primary structure and functional
characteristics of a mammalian sodium-coupled high affinity dicarboxylate transporter. J. Biol. Chem.
274(6):3422–29
46. Kinoshita K. 1931. U¨ber eine neue Aspergillus-Art, Asp. itaconicus nov. spec. Bot. Mag. Tokyo 45:45–50
47. Klement T, Bu¨chs J. 2013. Itaconic acid—a biotechnological process in change. Bioresour. Technol.
135:422–31
48. Knowles RG, Moncada S. 1994. Nitric oxide synthases in mammals. Biochem. J. 298(Part 2):249–58
49. Kominsky DJ, Campbell EL, Colgan SP. 2010. Metabolic shifts in immunity and inflammation.
J. Immunol. 184(8):4062–68
50. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, et al. 2010. Toll-like receptor-induced changes in
glycolytic metabolism regulate dendritic cell activation. Blood 115(23):4742–49
51. Kumar R. 2009. Glyoxylate shunt: combating mycobacterium at forefront. Int. J. Integr. Biol. 7(2):69–
72
52. Larsen BYH, Eimhjellen KE. 1954. The mechanism of itaconic acid formation by Aspergillus terreus. 1.
The effect of acidity. Biochem. J. 6:135–39
53. Lee Jenkins NA, Gilbert DJ, CopelandNG, O’BrienWE. 1995. Cloning and analysis of gene regulation
of a novel LPS-inducible cDNA. Immunogenetics 41(5):263–70
54. Li H, Gang Z, Yuling H, Luokun X, Jie X, et al. 2006. Different neurotropic pathogens elicit neurotoxic
CCR9- or neurosupportive CXCR3-expressing microglia. J. Immunol. 177(6):3644–56
55. Li Y, Zhang P,Wang C, Han C, Meng J, et al. 2013. Immune responsive gene 1 (IRG1) promotes endo-
toxin tolerance by increasing A20 expression in macrophages through ROS. J. Biol. Chem. 1(23):16225–
34
12.20 Cordes · Michelucci · Hiller
Changes may still occur before final publication online and in print
An
nu
. R
ev
. N
utr
. 2
01
5.3
5. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y C
op
yri
gh
t C
lea
ran
ce
 C
en
ter
 on
 05
/18
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
NU35CH12-Hiller ARI 4 May 2015 15:10
56. Lin Y-H, Li Y-F, Huang M-C, Tsai Y-C. 2004. Intracellular expression of vitreoscilla hemoglobin
in Aspergillus terreus to alleviate the effect of a short break in aeration during culture. Biotechnol. Lett.
26(13):1067–72
57. Maassen N, Panakova M, Wierckx N, Geiser E, Zimmermann M, et al. 2014. Influence of carbon and
nitrogen concentration on itaconic acid production by the smut fungus Ustilago maydis. Eng. Life Sci.
14(2):129–34
58. Martin WR, Frigan F, Bergman EEH. 1961. Noninductive metabolism of itaconic acid by Pseudomonas
and Salmonella species. J. Bacteriol. 82(6):905–8
59. McFadden BA, Purohit S. 1977. Itaconate, an isocitrate lyase-directed inhibitor inPseudomonas indigofera.
J. Bacteriol. 131(1):136–44
60. McFadden BA,Williams JO, Roche TE. 1971. Mechanism of action of isocitrate lyase from Pseudomonas
indigofera. Biochemistry 10(8):1384–90
61. McKinney JD, Ho¨ner zu Bentrup K, Mun˜oz-Elı´as EJ, Miczak A, Chen B, et al. 2000. Persistence of
Mycobacterium tuberculosis in macrophages andmice requires the glyoxylate shunt enzyme isocitrate lyase.
Nature 406(6797):735–38
62. Meissner F, Scheltema RA, Mollenkopf H-J, Mann M. 2013. Direct proteomic quantification of the
secretome of activated immune cells. Science 340(6131):475–78
63. Me´nage S, Attre´e I. 2014. Pathogens love the poison. Nat. Chem. Biol. 10(5):326–27
64. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, et al. 2013. Immune-responsive gene 1 protein
links metabolism to immunity by catalyzing itaconic acid production. PNAS 110(19):7820–25
65. Mills E, O’Neill LAJ. 2014. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 24(5):313–20
66. Mor G, Cardenas I, Abrahams V, Guller S. 2011. Inflammation and pregnancy: the role of the immune
system at the implantation site. Ann. N. Y. Acad. Sci. 1221:80–87
67. Mosser DM. 2003. The many faces of macrophage activation. J. Leukoc. Biol. 73(2):209–12
68. Mun˜oz-Elias EJ. 2006.Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo
growth and virulence. Nat. Med. 11(6):638–44
69. Mun˜oz-Elı´as EJ, McKinney JD. 2006. Carbon metabolism of intracellular bacteria. Cell. Microbiol.
8(1):10–22
70. Nelson KK, Melendez JA. 2004. Mitochondrial redox control of matrix metalloproteinases. Free Radic.
Biol. Med. 37(6):768–84
71. O’Neill LAJ, Hardie DG. 2013. Metabolism of inflammation limited by AMPK and pseudo-starvation.
Nature 493(7432):346–55
72. Okabe M, Lies D, Kanamasa S, Park EY. 2009. Biotechnological production of itaconic acid and its
biosynthesis in Aspergillus terreus. Appl. Microbiol. Biotechnol. 84(4):597–606
73. Okabe M, Ohta N, Park YS. 1993. Itaconic acid production in an air-lift bioreactor using a modified
draft tube. J. Ferment. Bioeng. 76(2):117–22
74. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol.
PNAS 105(11):4376–80
75. Patel TR, McFadden BA. 1978. Caenorhabditis elegans and Ascaris suum: inhibition of isocitrate lyase by
itaconate. Exp. Parasitol. 44(2):262–68
76. Pearce EL, Pearce EJ. 2013. Metabolic pathways in immune cell activation and quiescence. Immunity
38(4):633–43
77. PreusseM,TantawyMA,KlawonnF, Schughart K, Pessler F. 2013. Infection- and procedure-dependent
effects on pulmonary gene expression in the early phase of influenza A virus infection in mice. BMC
Microbiol. 13:293
78. Rodrı´guez-Prados J-C, Trave´s PG, Cuenca J, Rico D, Aragone´s J, et al. 2010. Substrate fate in activated
macrophages: a comparison between innate, classic, and alternative activation. J. Immunol. 185(1):605–14
79. Russell DG, Vanderven BC, LeeW, Abramovitch RB, Homolka S, et al. 2010.Mycobacterium tuberculosis
wears what it eats. Cell Host Microbe 8(1):68–76
80. Sakai A, Kusumoto A, Kiso Y, Furuya E. 2004. Itaconate reduces visceral fat by inhibiting fructose
2,6-bisphosphate synthesis in rat liver. Nutrition 20(11–12):997–1002
81. Sasikaran J, Ziemski M, Zadora PK, Fleig A, Berg IA. 2014. Bacterial itaconate degradation promotes
pathogenicity. Nat. Chem. Biol. 10:371–77
www.annualreviews.org • Itaconic Acid as a Mammalian Antimicrobial Metabolite 12.21
Changes may still occur before final publication online and in print
An
nu
. R
ev
. N
utr
. 2
01
5.3
5. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y C
op
yri
gh
t C
lea
ran
ce
 C
en
ter
 on
 05
/18
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
NU35CH12-Hiller ARI 4 May 2015 15:10
82. Schiavone N, Rosini P, Quattrone A, Donnini M, Lapucci A, et al. 2000. A conserved AU-rich element
in the 3′ untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in
bcl-2 down-regulation during apoptosis. FASEB J. 14(1):174–84
83. Sena LA, Chandel NS. 2012. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell
48(2):158–67
84. Sharma V, Sharma S, Hoener K, McKinney JD, Russell DG, et al. 2000. Structure of isocitrate lyase,
Mycobacterium tuberculosis. Nat. Struct. Biol. 7(8):663–68
85. Shi S, Blumenthal A, Hickey CM, Gandotra S, Levy D, Ehrt S. 2005. Expression of many immunolog-
ically important genes inMycobacterium tuberculosis-infected macrophages is independent of both TLR2
and TLR4 but dependent on IFN-αβ receptor and STAT1. J. Immunol. 175(5):3318–28
86. Shin J-H, Yang J-Y, Jeon B-Y, Yoon Y-JJ, Cho S-N, et al. 2011. 1H NMR-based metabolomic profiling
in mice infected withMycobacterium tuberculosis. J. Proteome Res. 10(5):2238–47
87. Smith J, Sadeyen J-R, Paton IR, Hocking PM, Salmon N, et al. 2011. Systems analysis of immune
responses in Marek’s disease virus-infected chickens identifies a gene involved in susceptibility and
highlights a possible novel pathogenicity mechanism. J. Virol. 85(21):11146–58
88. Steiger MG, Blumhoff ML, Mattanovich D, Sauer M. 2013. Biochemistry of microbial itaconic acid
production. Front. Microbiol. 4:23
89. Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, et al. 2011. Itaconic acid is a mammalian
metabolite induced during macrophage activation. J. Am. Chem. Soc. 133(41):16386–89
90. Strelkov S, vonElstermannM, SchomburgD. 2004. Comprehensive analysis ofmetabolites inCorynebac-
terium glutamicum by gas chromatography/mass spectrometry. Biol. Chem. 385(9):853–61
91. Sugimoto M, Sakagami H, Yokote Y, Onuma H, Kaneko M, et al. 2011. Non-targeted metabolite
profiling in activated macrophage secretion.Metabolomics 8(4):624–33
92. SvinengG,Ravuri C, RikardsenO,HusebyN-E,Winberg J-O. 2008.The role of reactive oxygen species
in integrin and matrix metalloproteinase expression and function. Connect. Tissue Res. 49(3):197–202
93. Tabuchi T, Sigisawa T, Ishidori T, Nakahara T, Sugiyama J. 1981. Itaconic acid fermentation by a yeast
belonging to the genus Candida. Agric. Biol. Chem. 45(2):475–79
94. Tanaka Y, Adams DH, Shaw S. 1993. Proteoglycans on endothelial cells present adhesion-inducing
cytokines to leukocytes. Immunol. Today 14(3):111–15
95. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, et al. 2013. Succinate
is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496(7444):238–42
96. Terakawa J, Wakitani S, Sugiyama M, Inoue N, Ohmori Y, et al. 2011. Embryo implantation is blocked
by intraperitoneal injection with anti-LIF antibody in mice. J. Reprod. Dev. 57(6):700–7
97. Thomas DM, Francescutti-Verbeem DM, Kuhn DM. 2006. Gene expression profile of activated mi-
croglia under conditions associated with dopamine neuronal damage. FASEB J. 20(3):515–17
98. Turner E. 1840. Elements of Chemistry: Including the Recent Discoveries and Doctrines of the Science. Philadel-
phia: Cowperthwait & Co.
99. Upton AM, McKinney JD. 2007. Role of the methylcitrate cycle in propionate metabolism and detoxi-
fication inMycobacterium smegmatis.Microbiology 153(Part 12):3973–82
100. Van der Geize R, Yam K, Heuser T, Wilbrink MH, Hara H, et al. 2007. A gene cluster encoding
cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in
macrophages. PNAS 104(6):1947–52
101. Van der Straat L, Vernooij M, Lammers M, van den Berg W, Schonewille T, et al. 2014. Expression of
the Aspergillus terreus itaconic acid biosynthesis cluster in Aspergillus niger.Microb. Cell Fact. 13(1):11
102. Van Schaik EJ, Tom M, Woods DE. 2009. Burkholderia pseudomallei isocitrate lyase is a persistence
factor in pulmonary melioidosis: implications for the development of isocitrate lyase inhibitors as novel
antimicrobials. Infect. Immun. 77(10):4275–83
103. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the
metabolic requirements of cell proliferation. Science 324(5930):1029–33
104. Wang SF, Adler J, Lardy HA. 1961. The pathway of itaconate metabolism by liver mitochondria. J. Biol.
Chem. 236:26–30
105. WestAP,Brodsky IE,RahnerC,WooDK,Erdjument-BromageH, et al. 2011.TLRsignalling augments
macrophage bactericidal activity through mitochondrial ROS. Nature 472(7344):476–80
12.22 Cordes · Michelucci · Hiller
Changes may still occur before final publication online and in print
An
nu
. R
ev
. N
utr
. 2
01
5.3
5. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y C
op
yri
gh
t C
lea
ran
ce
 C
en
ter
 on
 05
/18
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
NU35CH12-Hiller ARI 4 May 2015 15:10
106. Willke T, Vorlop KD. 2001. Biotechnological production of itaconic acid. Appl. Microbiol. Biotechnol.
56(3–4):289–95
107. Xiao W, Wang L, Xiao R, Wu M, Tan J, He Y. 2011. Expression profile of human immune-responsive
gene 1 and generation and characterization of polyclonal antiserum.Mol. Cell Biochem. 353(1–2):177–87
108. Yahiro K, Takahama T, Jai S, Park Y, Okabe M. 1997. Comparison of air-lift and stirred tank reactors
for itaconic acid production by Aspergillus terreus. Biotechnol. Lett. 19(7):619–21
109. Yahiro K, Takahama T, Park YS, Okabe M. 1995. Breeding of Aspergillus terreus mutant TN-484 for
itaconic acid production with high yield. J. Ferment. Bioeng. 79(5):506–8
110. Zinchenko VP, Goncharov NV, Teplova VV, Kasymov VA, Petrova OI, et al. 2007. Interaction of
intracellular signalling and metabolic pathways at inhibition of mitochondrial aconitase by fluoroacetate.
Cell Tissue Biol. 1(6):541–50
www.annualreviews.org • Itaconic Acid as a Mammalian Antimicrobial Metabolite 12.23
Changes may still occur before final publication online and in print
An
nu
. R
ev
. N
utr
. 2
01
5.3
5. 
Do
wn
loa
de
d f
rom
 w
ww
.an
nu
alr
ev
iew
s.o
rg
 A
cc
ess
 pr
ov
ide
d b
y C
op
yri
gh
t C
lea
ran
ce
 C
en
ter
 on
 05
/18
/15
. F
or 
pe
rso
na
l u
se 
on
ly.
